RecruitingPhase 3NCT07024563

Study of Ravulizumab in Pediatric Participants With Primary IgAN

A Phase 3, Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Ravulizumab in Pediatric Participants (2 to < 18 Years of Age) With Primary Immunoglobulin A Nephropathy (IgAN)

Sponsor

Alexion Pharmaceuticals, Inc.

Enrollment

24 participants

Start Date

Jun 14, 2025

Study Type

INTERVENTIONAL

Conditions

Immunoglobulin A Nephropathy IgAN IgA Vasculitis IgAVN Immunoglobulin A Vasculitis Associated Nephritis Henoch-schonlein Purpura Nephritis

Summary

The primary objectives of this study are to characterize ravulizumab pharmacokinetics (PK) and pharmacodynamics (PD), and to evaluate safety and efficacy following ravulizumab IV dosing in pediatric participants with IgAN or IgAVN.

Eligibility

Min Age: 2 YearsMax Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Ravulizumab for people with henoch-schonlein purpura nephritis, iga vasculitis, and other related conditions. The study is currently recruiting participants at 14 locations. People eligible for this study include aged 2 Years to 18 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGRavulizumab

Participants will receive Ravulizumab via intravenous (IV) infusion.

Locations(14)

Research Site

Palo Alto, California, United States

Research Site

Aurora, Colorado, United States

Research Site

Beijing, China

Research Site

Shanghai, China

Research Site

Genova, Italy

Research Site

Roma, Italy

Research Site

Torino, Italy

Research Site

Wakayama, Japan

Research Site

Seoul, South Korea

Research Site

Barcelona, Spain

Research Site

Barcelona, Spain

Research Site

Seville, Spain

Research Site

Taipei, Taiwan

Research Site

Taoyuan, Taiwan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07024563

Related Trials

Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN

NCT074983356 locations

Atacicept in Multiple Glomerular Diseases

NCT069830281 location

I-FABP as a Predictor of Gastrointestinal Involvement in Pediatric IgA Vasculitis

NCT076642281 location

Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease

NCT0698935929 locations

A Study of the Safety and Activity of Sparsentan for the Treatment of Patients With Immunoglobulin A Nephropathy

NCT046632046 locations